Liraglutide and Heart Failure in Type 2 Diabetes
NCT01425580 on ClinicalTrials.gov · last registry update 2016-09-01
Finished August 2016, after enrolling 62 people. liraglutide is approved in the US, but not for heart failure — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P2
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Thomas Nystrom
- Sponsor type
- Other
- Enrollment
- 62
- Started
- 2012-01
- Primary completion
- 2016-08 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Left ventricle longitudinal function and/or functional reserve during rest and/or after exercise using tissue Doppler echocardiography
Conditions studied
Congestive Heart Failure · Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.